Regeneron Pharmaceuticals (REGN) 291.39 $REGN
Regeneron Earnings: Is Now the Time to Buy?
Leo Sun, The Motley Fool - Motley Fool - Mon May 12, 2:25PM CDT
Regeneron reported its first-quarter earnings on May 8, topping analyst expectations on both the top and bottom lines. Regeneron's non-GAAP diluted earnings rose 27% year over year to $2.26 per share, or $263 million, topping the...
Collaborations, Conference Schedules, Financial Results, and Recognitions - Analyst Notes on Regeneron, Thermo Fisher, Zoetis, Aetna and GSK
PR Newswire - Fri May 09, 10:30AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Thermo Fisher Scientific, Inc. (NYSE: TMO), Zoetis Inc. (NYSE: ZTS), Aetna Inc. (NYSE: AET) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2260-100free.
Earnings Up at Jazz Pharma, Guidance Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:40AM CDT
Jazz Pharmaceuticals reported first quarter 2014 adjusted (including stock-based compensation expense and depreciation) earnings of $1.51 per share.
Regeneron Beats on Earnings, Revenues in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 12:27PM CDT
Regeneron (REGN) beat on earnings and revenues in the quarter.
Regeneron's Profit Soared 31% on Higher Collaboration Revenue and Eylea Sales
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 10:59AM CDT
Shareholders of Regeneron Pharmaceuticals can certainly see a little clearer now after their company once again delivered impressive growth in the first quarter on the heels of its blockbuster ophthalmic drug, Eylea. For the quarter, total...
Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed
at Investor's Business Daily - Thu May 08, 10:19AM CDT
Canadian drugmaker Valeant Pharmaceuticals International (VRX) reported a mixed but mostly in-line Q1 Thursday, as management continued to press its case for a merger with Allergan (AGN). Valeant's stock rose fractionally on the stock market today....
Regeneron Reports First Quarter 2014 Financial and Operating Results
PR Newswire - Thu May 08, 5:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the first quarter of 2014 and provided an update on development programs.
Will Regeneron (REGN) Disappoint in Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 4:20PM CDT
Regeneron (REGN) is set to report its first quarter 2014 results on Feb 8 before the opening bell.
Look for Shares of Regeneron Pharmaceuticals to Potentially Rebound after Yesterday's 1.43% Sell Off
Comtex SmarTrend(R) - Wed May 07, 4:19PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $283.56 to a high of $294.49. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $289.73 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Hypercholesterolemia - Pipeline Review, H1 2014: 22 Company and 41 Drug Profiled
M2 - Wed May 07, 9:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sxbqm/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Alnylam Pharmaceuticals, Inc. - Amgen Astellas BioPharma K.K. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Dybly AG - Eli Lilly and Company - Esperion Therapeutics, Inc. - FORMAC Pharmaceuticals N.V. - Immune Response BioPharma, Inc. - Johnson & Johnson - LondonPharma Ltd - Lumena Pharmaceuticals, Inc. - Madeira Therapeutics - Merck & Co., Inc. - NanoForm Therapeutics Ltd. - Pfizer Inc. - Planet Biotechnology Inc. - Regeneron Pharmaceuticals, Inc. - Relypsa, Inc. - Santaris Pharma A/S - Serometrix, LLC - Zhejiang Hisun Pharmaceutical Co., Ltd. Drug Profiles: - anacetrapib - alirocumab - evolocumab - bococizumab - ETC-1002 - Alpha Cyclodextrin - evolocumab - BMS-770767 - bococizumab - LY-3015014 - CAT-2003 - SPC-4955 - MGL-3196 - ALN-PCS02 - SPC-5001 - BMS-962476 - ralpancizumab - BMS-852927 - fenofibrate - simvastatin - fluvastatin sodium - pravastatin sodium - LUM-002 - PF-06678552 - HS-25 - ALN-PCS02 - RLY-106 - atorvastatin calcium - 1D05-Fab - IR-1002 For more information visit http://www.researchandmarkets.com/research/7s...lesterolem
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week.
Regeneron Inks Ophthalmology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 4:20PM CDT
In a bid to boost its ophthalmology portfolio, Regeneron (REGN) inked a deal with Avalanche Biotechnologies.
Regeneron-Avalanche Partnership Underscores Ohr Pharma's Eye-Disease Isolation
at The Street - Mon May 05, 8:54AM CDT
The Regeneron-Avalanche partnership and the hedge funds investment in the latter is more indirect evidence that Ohr Pharmaceuticals and its AMD eye drop Squalamine are not taken seriously.
Monday’s Top Health Care Stories: Pfizer, Auxilium, and Regeneron
Leo Sun, The Motley Fool - Motley Fool - Mon May 05, 8:20AM CDT
Let's take a look at three stocks -- Pfizer , Auxilium Pharmaceuticals , and Regeneron -- which could make waves across the health care sector this Monday morning. Pfizer misses revenue estimates for the first quarter First up,...
Regeneron and Avalanche Biotechnologies Announce Collaboration to Develop Next-Generation Gene Therapy Products in Ophthalmology
PR Newswire - Mon May 05, 7:27AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular BioFactory(TM), an adeno-associated virus (AAV)-based, proprietary, next-generation platform for the discovery and development of gene therapy vectors for ophthalmology.
Regeneron Announces Upcoming 2014 Investor Conference Presentations
PR Newswire - Fri May 02, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
Critical Alerts For LinkedIn, Morgan Stanley, Nordstrom, Regeneron Pharmaceuticals, and News Corp Released By InvestorsObserver
PR Newswire - Thu May 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LNKD, MS, JWN, REGN, and NWSA.
Awards, Stock Price Updates, Quarterly Earnings Releases, and Clinical Study Results - Analyst Notes on Aetna, Regeneron, Questcor, Medtronic and Lilly
PR Newswire - Thu May 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Aetna Inc. (NYSE: AET), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Medtronic Inc. (NYSE: MDT) and Eli Lilly & Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1903-100free.
Amicus Up on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:32PM CDT
Shares of Amicus Therapeutics (FOLD) shot up 20.7% after it announced positive data from its first phase III study on migalastat HCl monotherapy.
Sanofi Misses on Q1 Earnings, Lackluster Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 10:07AM CDT
Sanofi (SNY) reported first quarter 2014 business earnings of 80 cents per American Depositary Share.
Regeneron Earnings: Is Now the Time to Buy?
Leo Sun, The Motley Fool - Motley Fool - Mon May 12, 2:25PM CDT
Regeneron reported its first-quarter earnings on May 8, topping analyst expectations on both the top and bottom lines. Regeneron's non-GAAP diluted earnings rose 27% year over year to $2.26 per share, or $263 million, topping the...
Collaborations, Conference Schedules, Financial Results, and Recognitions - Analyst Notes on Regeneron, Thermo Fisher, Zoetis, Aetna and GSK
PR Newswire - Fri May 09, 10:30AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Thermo Fisher Scientific, Inc. (NYSE: TMO), Zoetis Inc. (NYSE: ZTS), Aetna Inc. (NYSE: AET) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2260-100free.
Earnings Up at Jazz Pharma, Guidance Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:40AM CDT
Jazz Pharmaceuticals reported first quarter 2014 adjusted (including stock-based compensation expense and depreciation) earnings of $1.51 per share.
Regeneron Beats on Earnings, Revenues in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 12:27PM CDT
Regeneron (REGN) beat on earnings and revenues in the quarter.
Regeneron's Profit Soared 31% on Higher Collaboration Revenue and Eylea Sales
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 10:59AM CDT
Shareholders of Regeneron Pharmaceuticals can certainly see a little clearer now after their company once again delivered impressive growth in the first quarter on the heels of its blockbuster ophthalmic drug, Eylea. For the quarter, total...
Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed
at Investor's Business Daily - Thu May 08, 10:19AM CDT
Canadian drugmaker Valeant Pharmaceuticals International (VRX) reported a mixed but mostly in-line Q1 Thursday, as management continued to press its case for a merger with Allergan (AGN). Valeant's stock rose fractionally on the stock market today....
Regeneron Reports First Quarter 2014 Financial and Operating Results
PR Newswire - Thu May 08, 5:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the first quarter of 2014 and provided an update on development programs.
Will Regeneron (REGN) Disappoint in Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 4:20PM CDT
Regeneron (REGN) is set to report its first quarter 2014 results on Feb 8 before the opening bell.
Look for Shares of Regeneron Pharmaceuticals to Potentially Rebound after Yesterday's 1.43% Sell Off
Comtex SmarTrend(R) - Wed May 07, 4:19PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $283.56 to a high of $294.49. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $289.73 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Hypercholesterolemia - Pipeline Review, H1 2014: 22 Company and 41 Drug Profiled
M2 - Wed May 07, 9:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sxbqm/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Alnylam Pharmaceuticals, Inc. - Amgen Astellas BioPharma K.K. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Dybly AG - Eli Lilly and Company - Esperion Therapeutics, Inc. - FORMAC Pharmaceuticals N.V. - Immune Response BioPharma, Inc. - Johnson & Johnson - LondonPharma Ltd - Lumena Pharmaceuticals, Inc. - Madeira Therapeutics - Merck & Co., Inc. - NanoForm Therapeutics Ltd. - Pfizer Inc. - Planet Biotechnology Inc. - Regeneron Pharmaceuticals, Inc. - Relypsa, Inc. - Santaris Pharma A/S - Serometrix, LLC - Zhejiang Hisun Pharmaceutical Co., Ltd. Drug Profiles: - anacetrapib - alirocumab - evolocumab - bococizumab - ETC-1002 - Alpha Cyclodextrin - evolocumab - BMS-770767 - bococizumab - LY-3015014 - CAT-2003 - SPC-4955 - MGL-3196 - ALN-PCS02 - SPC-5001 - BMS-962476 - ralpancizumab - BMS-852927 - fenofibrate - simvastatin - fluvastatin sodium - pravastatin sodium - LUM-002 - PF-06678552 - HS-25 - ALN-PCS02 - RLY-106 - atorvastatin calcium - 1D05-Fab - IR-1002 For more information visit http://www.researchandmarkets.com/research/7s...lesterolem
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week.
Regeneron Inks Ophthalmology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 4:20PM CDT
In a bid to boost its ophthalmology portfolio, Regeneron (REGN) inked a deal with Avalanche Biotechnologies.
Regeneron-Avalanche Partnership Underscores Ohr Pharma's Eye-Disease Isolation
at The Street - Mon May 05, 8:54AM CDT
The Regeneron-Avalanche partnership and the hedge funds investment in the latter is more indirect evidence that Ohr Pharmaceuticals and its AMD eye drop Squalamine are not taken seriously.
Monday’s Top Health Care Stories: Pfizer, Auxilium, and Regeneron
Leo Sun, The Motley Fool - Motley Fool - Mon May 05, 8:20AM CDT
Let's take a look at three stocks -- Pfizer , Auxilium Pharmaceuticals , and Regeneron -- which could make waves across the health care sector this Monday morning. Pfizer misses revenue estimates for the first quarter First up,...
Regeneron and Avalanche Biotechnologies Announce Collaboration to Develop Next-Generation Gene Therapy Products in Ophthalmology
PR Newswire - Mon May 05, 7:27AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular BioFactory(TM), an adeno-associated virus (AAV)-based, proprietary, next-generation platform for the discovery and development of gene therapy vectors for ophthalmology.
Regeneron Announces Upcoming 2014 Investor Conference Presentations
PR Newswire - Fri May 02, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
Critical Alerts For LinkedIn, Morgan Stanley, Nordstrom, Regeneron Pharmaceuticals, and News Corp Released By InvestorsObserver
PR Newswire - Thu May 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LNKD, MS, JWN, REGN, and NWSA.
Awards, Stock Price Updates, Quarterly Earnings Releases, and Clinical Study Results - Analyst Notes on Aetna, Regeneron, Questcor, Medtronic and Lilly
PR Newswire - Thu May 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Aetna Inc. (NYSE: AET), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Medtronic Inc. (NYSE: MDT) and Eli Lilly & Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1903-100free.
Amicus Up on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:32PM CDT
Shares of Amicus Therapeutics (FOLD) shot up 20.7% after it announced positive data from its first phase III study on migalastat HCl monotherapy.
Sanofi Misses on Q1 Earnings, Lackluster Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 10:07AM CDT
Sanofi (SNY) reported first quarter 2014 business earnings of 80 cents per American Depositary Share.
